[go: up one dir, main page]

PA8789101A1 - Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble - Google Patents

Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble

Info

Publication number
PA8789101A1
PA8789101A1 PA20088789101A PA8789101A PA8789101A1 PA 8789101 A1 PA8789101 A1 PA 8789101A1 PA 20088789101 A PA20088789101 A PA 20088789101A PA 8789101 A PA8789101 A PA 8789101A PA 8789101 A1 PA8789101 A1 PA 8789101A1
Authority
PA
Panama
Prior art keywords
pharmaceutical composition
hydrosoluble
salt
vinflunin
stable pharmaceutical
Prior art date
Application number
PA20088789101A
Other languages
English (en)
Inventor
Bruno Paillard
Jean Louis Avan
Joel Bougaret
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PA8789101A1 publication Critical patent/PA8789101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICIÓN FARMACÉUTICA ESTABLE FORMADA POR UNA SAL DE VINFLUNINA HIDROSOLUBLE Y AL MENOS UN DILUYENTE Y UN LUBRICANTE, ESTANDO DICHA COMPOSICIÓN EN FORMA SÓLIDA DESTINADA A SU USO POR VÍA ORAL. LA SAL HIDROSOLUBLE DE VINFLUNINA ES PREFERENTEMENTE DITRARTRATO DE VINFLUNINA, LA COMPOSICIÓN FARMACÉUTICA ESTÁ VENTAJOSAMENTE EN FORMA DE CÁPSULA O COMPRIMIDO. LA INVENCIÓN TAMBIÉN SE REFIERE A UN PROCEDIMIENTO PARA EL TRATAMIENTO DE UNA PATOLOGÍA CANCEROSA QUE COMPRENDE LA ADMINISTRACIÓN POR VÍA ORAL DE LA COMPOSICIÓN FARMACÉUTICA DE LA INVENCIÓN.
PA20088789101A 2007-07-11 2008-07-09 Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble PA8789101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0756421A FR2918566B1 (fr) 2007-07-11 2007-07-11 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US97033407P 2007-09-06 2007-09-06

Publications (1)

Publication Number Publication Date
PA8789101A1 true PA8789101A1 (es) 2009-04-23

Family

ID=38868376

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088789101A PA8789101A1 (es) 2007-07-11 2008-07-09 Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble

Country Status (21)

Country Link
US (1) US9173842B2 (es)
EP (1) EP2187886A1 (es)
JP (1) JP2010533139A (es)
KR (1) KR20100047230A (es)
CN (1) CN101730533B (es)
AR (1) AR067499A1 (es)
AU (1) AU2008274223A1 (es)
BR (1) BRPI0814216A2 (es)
CA (1) CA2695039A1 (es)
CL (1) CL2008002005A1 (es)
CO (1) CO6160316A2 (es)
FR (1) FR2918566B1 (es)
MA (1) MA32045B1 (es)
NZ (1) NZ583040A (es)
PA (1) PA8789101A1 (es)
RU (1) RU2462248C2 (es)
SA (1) SA08290417B1 (es)
TN (1) TN2010000013A1 (es)
TW (1) TW200914018A (es)
WO (1) WO2009007388A1 (es)
ZA (1) ZA201000335B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135856A2 (en) * 2011-04-01 2012-10-04 Spectrum Pharmaceuticals, Inc. Very low dose vinorelbine for treatment of cancer
WO2013145750A1 (ja) * 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
CN108289890B (zh) 2015-12-02 2021-04-27 日本新药株式会社 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物
CN106994121B (zh) * 2016-01-26 2021-07-02 江苏恒瑞医药股份有限公司 一种用于治疗癌症的药物组合物
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558053A (en) 1983-12-21 1985-12-10 Eli Lilly And Company Naphthalene-1,5-disulfonate salts of dimeric indole-dihydroindole alkaloids
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
AU2002213119A1 (en) 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
PT1530459E (pt) 2002-05-31 2010-05-20 Rp Scherer Technologies Llc Composição farmacêutica oral para cápsulas moles contendo vinorelbina e método de tratamento
US6890558B2 (en) * 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
WO2004099215A1 (ja) * 2003-05-09 2004-11-18 Keio University ビンカアルカロイドおよびその塩の利用
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
CZ296459B6 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
WO2006040779A2 (en) 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
BRPI0519466B8 (pt) * 2004-12-30 2021-05-25 Pf Medicament dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo
FR2880274B1 (fr) 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
FR2894966B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Nouvelle forme cristalline de la vinflunine
WO2009105937A1 (zh) 2008-02-29 2009-09-03 江苏豪森药业股份有限公司 长春瑞滨软胶囊及其制备方法和其应用

Also Published As

Publication number Publication date
WO2009007388A1 (en) 2009-01-15
TW200914018A (en) 2009-04-01
FR2918566B1 (fr) 2009-10-09
CO6160316A2 (es) 2010-05-20
CA2695039A1 (en) 2009-01-15
AR067499A1 (es) 2009-10-14
CN101730533B (zh) 2013-05-29
MA32045B1 (fr) 2011-02-01
JP2010533139A (ja) 2010-10-21
RU2462248C2 (ru) 2012-09-27
NZ583040A (en) 2012-03-30
RU2010103934A (ru) 2011-08-20
ZA201000335B (en) 2010-10-27
BRPI0814216A2 (pt) 2015-10-27
SA08290417B1 (ar) 2013-01-22
AU2008274223A1 (en) 2009-01-15
EP2187886A1 (en) 2010-05-26
CN101730533A (zh) 2010-06-09
US20100196468A1 (en) 2010-08-05
TN2010000013A1 (en) 2011-09-26
CL2008002005A1 (es) 2009-06-26
US9173842B2 (en) 2015-11-03
KR20100047230A (ko) 2010-05-07
FR2918566A1 (fr) 2009-01-16

Similar Documents

Publication Publication Date Title
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
GT201400111A (es) Triazolopiridinas sustituidas
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
PA8809601A1 (es) Combinación anti-retroviral
CU20120171A7 (es) Triazolopiridinas sustituidas
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
CO6400226A2 (es) Micrólido anti-inflamatorio
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
GT200600157A (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
GT201400042A (es) Compuesto de benzotiazolona
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
CL2008003780A1 (es) Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras.